CRO Pharmagene announces re-launch and lab acquisition
CRO Pharmagene Discovery Services has announced its re-launch, coinciding with its purchase of a human tissue laboratory business.
Pharmagene, originally founded in 1996, has acquired a business near Cambridge, UK. The company says the business is specialised in the performance of laboratory-based research services using consented human tissue across both preclinical and clinical settings.
“We are thrilled to be taking on the business and are grateful to the previous owners for agreeing to sell the business to us,” said Tom Mander, CEO and Co-Founder of Pharmagene.
“We inherit all the laboratory infrastructure, people and clients alongside all the know-how and expertise within the company.”
“During my 25 years here, there have been many exciting technology developments across our industry,” added Amanda Woodrooffe, CSO and Co-Founder.
“We have implemented new and advanced analytical platforms enabling a deep dive into understanding complex disease biology, developed tailored assays to support the emergence of advanced therapeutic modalities and, importantly, seen the broad adoption and impact of human tissue-based research supporting earlier decision making in the discovery and development of novel therapeutics.
“We apply our knowledge, experience, and innovative methods, maintaining a commitment to continuous learning and development to provide optimal scientific solutions tailored to each project.”
Richard Willock, CBO and Co-Founder, also said Pharmagene is “poised to grow strongly as the partner of choice for companies requiring deep expertise in human tissue-based research.”
